Chromocell Therapeutics Corporation (CHRO)

USD 0.59

(-4.76%)

Long Term Debt Summary of Chromocell Therapeutics Corporation

  • Chromocell Therapeutics Corporation's latest annual long term debt in 2023 was - USD , down 0.0% from previous year.
  • Chromocell Therapeutics Corporation's latest quarterly long term debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Chromocell Therapeutics Corporation reported annual long term debt of - USD in 2022, down -100.0% from previous year.
  • Chromocell Therapeutics Corporation reported annual long term debt of 1.09 Million USD in 2021, down 0.0% from previous year.
  • Chromocell Therapeutics Corporation reported quarterly long term debt of - USD for 2024 Q2, down 0.0% from previous quarter.
  • Chromocell Therapeutics Corporation reported quarterly long term debt of - USD for 2023 FY, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Chromocell Therapeutics Corporation (2023 - 2020)

Historical Annual Long Term Debt of Chromocell Therapeutics Corporation (2023 - 2020)

Year Long Term Debt Long Term Debt Growth
2023 - USD 0.0%
2022 - USD -100.0%
2021 1.09 Million USD 0.0%
2020 - USD 0.0%

Peer Long Term Debt Comparison of Chromocell Therapeutics Corporation

Name Long Term Debt Long Term Debt Difference
AIM ImmunoTech Inc. 495 Thousand USD 100.0%
Ampio Pharmaceuticals, Inc. - USD NaN%
Armata Pharmaceuticals, Inc. 82.3 Million USD 100.0%
Actinium Pharmaceuticals, Inc. 1.57 Million USD 100.0%
Azitra, Inc. 563.69 Thousand USD 100.0%
Can-Fite BioPharma Ltd. 13 Thousand USD 100.0%
Calidi Biotherapeutics, Inc. 2.06 Million USD 100.0%
CEL-SCI Corporation 11.6 Million USD 100.0%
iBio, Inc. 3.5 Million USD 100.0%
Lineage Cell Therapeutics, Inc. 2.07 Million USD 100.0%
MAIA Biotechnology, Inc. - USD NaN%
Matinas BioPharma Holdings, Inc. 2.89 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD 100.0%
NovaBay Pharmaceuticals, Inc. 1.1 Million USD 100.0%
NanoViricides, Inc. - USD NaN%
Oragenics, Inc. - USD NaN%
BiomX Inc. 5.4 Million USD 100.0%
BiomX Inc. 5.4 Million USD 100.0%
Protalix BioTherapeutics, Inc. 4.62 Million USD 100.0%
Palatin Technologies, Inc. 163.78 Thousand USD 100.0%
Scorpius Holdings, Inc. 12.61 Million USD 100.0%